Background: Cannabis use has a negative impact on psychosis. Studies are needed to explore the efficacy of psychological interventions to reduce cannabis use in psychosis. Our aim is to study the efficacy of a specific motivational intervention on young cannabis users suffering from psychosis. Methods: Participants (aged less than 35 years) were randomly assigned to treatment as usual (TAU) alone, or treatment as usual plus motivational intervention (MI + TAU). TAU was comprehensive and included case management, early intervention and mobile team when needed. Assessments were completed at baseline and at 3, 6 and12 months follow-up. Results: Sixty-two participants (32 TAU and 30 MI + TAU) were included in the study. Cannabis use decreased in both groups at follow-up. Participants who received MI in addition to TAU displayed both a greater reduction in number of joints smoked per week and greater confidence to change cannabis use at 3 and 6 months follow-up, but differences between groups were nonsignificant at 12 months. Conclusions: MI is well accepted by patients suffering from psychosis and has a short-term impact on cannabis use when added to standard care. However, the differential effect was not maintained at 1-year follow-up. MI appears to be a useful active component to reduce cannabis use which should be integrated in routine clinical practice.

Keywords:
Cannabis, Psychological intervention, Psychosis, Schizophrenia, Substance use disorders, Randomized controlled trial
1.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–2518.
2.
Degenhardt L, Hall W: The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001;31:659–668.
3.
Green AI, Drake RE, Brunette MF, Noordsy DL: Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007;164:402–408.
4.
Gregg L, Barrowclough C, Haddock G: Reasons for increased substance use in psychosis. Clin Psychol Rev 2007;27:494–510.
5.
Modestin J, Nussbaumer C, Angst K, Scheidegger P, Hell D: Use of potentially abusive psychotropic substances in psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1997;247:146–153.
6.
Bonsack C, Camus D, Kaufmann N, Aubert AC, Besson J, Baumann P, Borgeat F, Gillet M, Eap CB: Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. Addict Behav 2006;31:1252–1258.
7.
Conus P, Cotton S, Schimmelmann BG, McGorry PD, Lambert M: The First Episode Psychosis Outcome Study (FEPOS): pre-morbid and baseline characteristics of 704 first episode psychosis patients treated in EPPIC between 1998 and 2000. Early Intervention Psychiatry 2007;1:191–200.
8.
Rathbone J, Variend H, Mehta H: Cannabis and schizophrenia. Cochrane Database Syst Rev 2008;3:CD004837.
9.
Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD: Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 2006;81:145–150.
10.
Hides L, Dawe S, Kavanagh DJ, Young RM: Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry 2006;189:137–143.
11.
Ajdacic-Gross V, Lauber C, Warnke I, Haker H, Murray RM, Rossler W: Changing incidence of psychotic disorders among the young in Zurich. Schizophr Res 2007;95:9–18.
12.
Lenior ME, Dingemans PM, Schene AH, Linszen DH: Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophr Bull 2005;31:781–791.
13.
Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193:357–363.
14.
Baker AL, Hides L, Lubman DI: Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 2010;71:247–254.
15.
Haddock G, Barrowclough C, Tarrier N, Moring J, O’Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, McGovern J, Lewis S: Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. Br J Psychiatry 2003;183:418–426.
16.
Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O’Brien R, Schofield N, McGovern J: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706–1713.
17.
Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, McGorry PD: Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006;114:109–117.
18.
Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ: Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2006;188:439–448.
19.
Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon SD, Ockene J, Kaplan R: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009;78:275–284.
20.
Bonsack C, Montagrin Y, Favrod J, Gibellini S, Conus P: Une intervention motivationnelle brève adaptée aux consommateurs de cannabis souffrant de psychose. Encephale 2007;33:819–826.
21.
Miller WR: Motivational interviewing: research, practice, and puzzles. Addict Behav 1996;21:835–842.
22.
Edwards J, Mark H, Elkins K, Athanasopoulos O: Cannabis and first episode psychosis: the CAP project; in Graham HL, Copello A, Birchwood MJ, Mueser KT (eds): Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, Wiley & Sons, 2003
23.
Martino S, Carroll K, Kostas D, Perkins J, Rounsaville B: Dual diagnosis motivational interviewing: a modification of motivational interviewing for substance-abusing patients with psychotic disorders. J Subst Abuse Treat 2002;23:297–308.
24.
Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M: Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr Scand 2002;106:233–240.
25.
Ziedonis DM, Trudeau K: Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. Schizophr Bull 1997;23:229–238.
26.
Miller WR, Rose GS: Toward a theory of motivational interviewing. Am Psychol 2009;64:527–537.
27.
Prochaska JO, DiClemente CC: Toward a comprehensive model of change; in Miller WR, Heather N (eds): Treating Addictive Behaviours: Processes of Change. New York, Plenum, 1986, pp 3–27.
28.
Van Horn DH, Bux DA: A pilot test of motivational interviewing groups for dually diagnosed inpatients. J Subst Abuse Treat 2001;20:191–195.
29.
Fals-Stewart W, O’Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P: The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 2000;68:134–144.
30.
Daeppen JB, Gaume J, Bady P, Yersin B, Calmes JM, Givel JC, Gmel G: Brief alcohol intervention and alcohol assessment do not influence alcohol use in injured patients treated in the emergency department: a randomized controlled clinical trial. Addiction 2007;102:1224–1233.
31.
OMS: Classification internationale des troubles mentaux et des troubles du comportement: critères diagnostiques pour la recherche. Genève/Paris, WHO/Masson, 1994.
32.
Biener L, Abrams DB: The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 1991;10:360–365.
33.
Rollnick S, Mason P, Butler C: Health Behavior Change. Edinburgh, Churchill Livingstone, 2000.
34.
Guelfi JD: The PANSS (Positive And Negative Symptom) Scale (in French). Encephale 1997;23(Spec No 2):35–38.
35.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull 1987;13:261–276.
36.
Boyer P: EGF; in Guelfi JD (ed): L’évaluation clinique standardisée en psychiatrie. Éditions Pierre Fabre, 1996, tome 1.
37.
Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766–771.
38.
Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B: Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br J Psychiatry Suppl 2000;39:s28–s33.
39.
Rosenthal R: Meta-Analytic Procedures for Social Research. Newbury Park, Sage, 1991.
40.
Field A: Discovering Statistics Using SPSS. London, Sage, 2005.
41.
Cohen J: Statistical Power Analysis for the Behavioural Sciences. Hillsdale, Erlbaum, 1988.
42.
Cleary M, Hunt G, Matheson S, Siegfried N, Walter G: Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2008;23:CD001088.
43.
Colagiuri B, Morley K, Boakes R, Haber P: Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence. Psychother Psychosom 2009;78:167–171.
44.
Donohue B, Hill HH, Azrin NH, Cross C, Strada MJ: Psychometric support for contemporaneous and retrospective youth and parent reports of adolescent marijuana use frequency in an adolescent outpatient treatment population. Addict Behav 2007;32:1787–1797.
45.
Hjorthøj C, Fohlmann A, Larsen AM, Madsen MT, Vesterager L, Gluud C, Arendt MC, Nordentoft M: Design paper: the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Trials 2008;9:42.
46.
Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG: The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112:141–148.
47.
Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, González-Pinto A, Payá B, Soutullo C, de la Serna E, Arango C: Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 2009;113:129–137.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.